Hemagglutination inhibition antibody titers as a correlate of protection against seasonal A/H3N2 influenza disease

作者: Anne Benoit , Jiri Beran , Jeanne-Marie Devaster , Meral Esen , Odile Launay

DOI: 10.1093/OFID/OFV067

关键词:

摘要: Background. To investigate the relationship between hemagglutinin-inhibition (HI) antibody levels to risk of influenza disease, we conducted a correlate protection analysis using pooled data from previously published randomized trials. Methods. Data on occurrence laboratory-confirmed and HI pre- postvaccination were analyzed 4 datasets: 3 datasets included subjects aged <65 years who received inactivated trivalent vaccine (TIV) or placebo, 1 dataset ≥65 AS03-adjuvanted TIV (AS03TIV) TIV. A logistic model was used evaluate titer A/H3N2 antibodies disease. We then built receiver-operating characteristic curve identify potential cutoff no protection. Results. The baseline odds ratio disease higher for than in seasons strong epidemic intensity moderate low intensity. Including age as covariates, 4-fold increase associated with 2-fold decrease Conclusions. modeling exercise confirmed responses, but it did not allow an evaluation predictive power response.

参考文章(15)
Siber Gr, Methods for estimating serological correlates of protection. Developments in biological standardization. ,vol. 89, pp. 283- 296 ,(1997)
Steven Black, Uwe Nicolay, Timo Vesikari, Markus Knuf, Giuseppe Del Giudice, Giovanni Della Cioppa, Theodore Tsai, Ralf Clemens, Rino Rappuoli, Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children Pediatric Infectious Disease Journal. ,vol. 30, pp. 1081- 1085 ,(2011) , 10.1097/INF.0B013E3182367662
Laurent Coudeville, Fabrice Bailleux, Benjamin Riche, Françoise Megas, Philippe Andre, René Ecochard, Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model BMC Medical Research Methodology. ,vol. 10, pp. 18- 18 ,(2010) , 10.1186/1471-2288-10-18
Shu Li, Milton Parnes, Ivan S. F. Chan, Determining the cutoff based on a continuous variable to define two populations with application to vaccines. Journal of Biopharmaceutical Statistics. ,vol. 23, pp. 662- 680 ,(2013) , 10.1080/10543406.2012.756502
Norbert W. Hehme, Walter K??nzel, Frank Petschke, Gisela T??rk, Carmen Raderecht, Christian van Hoecke, Roland S??nger, TEN YEARS OF EXPERIENCE WITH THE TRIVALENT SPLIT-INFLUENZA VACCINE, FLUARIX Clinical Drug Investigation. ,vol. 22, pp. 751- 769 ,(2002) , 10.2165/00044011-200222110-00004
Danuta M. Skowronski, Flavia S. Moser, Naveed Z. Janjua, Bahman Davoudi, Krista M. English, Dale Purych, Martin Petric, Babak Pourbohloul, H3N2v and Other Influenza Epidemic Risk Based on Age-Specific Estimates of Sero-Protection and Contact Network Interactions PLOS ONE. ,vol. 8, ,(2013) , 10.1371/JOURNAL.PONE.0054015
Jiří Beran, Veronika Wertzova, Karel Honegr, Eva Kaliskova, Martina Havlickova, Jiří Havlik, Helena Jirincova, Pascale Van Belle, Varsha Jain, Bruce Innis, Jeanne-Marie Devaster, Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example BMC Infectious Diseases. ,vol. 9, pp. 2- 2 ,(2009) , 10.1186/1471-2334-9-2
Mark J Kelly, Frank D Dunstan, Keith Lloyd, David L Fone, Evaluating cutpoints for the MHI-5 and MCS using the GHQ-12: a comparison of five different methods BMC Psychiatry. ,vol. 8, pp. 10- 10 ,(2008) , 10.1186/1471-244X-8-10
D. Hobson, R. L. Curry, A. S. Beare, A. Ward-Gardner, The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. Journal of Hygiene. ,vol. 70, pp. 767- 777 ,(1972) , 10.1017/S0022172400022610
Lisa A Jackson, Manjusha J Gaglani, Harry L Keyserling, John Balser, Nancy Bouveret, Louis Fries, John J Treanor, Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons BMC Infectious Diseases. ,vol. 10, pp. 71- 71 ,(2010) , 10.1186/1471-2334-10-71